建業新生活有限公司

Central China New Life Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9983)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2024 ANNUAL REPORT

Reference is made to the annual report (the "**2024 Annual Report**") of Central China New Life Limited (the "**Company**") for the year ended 31 December 2024. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those used in the 2024 Annual Report.

In addition to the information disclosed in the 2024 Annual Report, the Company would like to provide to the Shareholders with the following additional information pursuant to Rules 17.07(1)(d) and 17.09(3) of the Listing Rules.

2023 SHARE AWARD SCHEME

On 29 May 2023, an aggregate of 21,800,000 awarded shares (the "**2023 Awarded Shares**") of the Company were conditionally granted by the Company pursuant to the 2023 Share Award Scheme. Such grants became unconditional on 7 August 2023. The details of the 2023 Share Award Scheme and the 2023 Awarded Shares were set out in the paragraph headed "2023 Share Award Scheme" in the 2024 Annual Report.

The weighted average closing price of Shares immediately before the date on which the 2023 Awarded Shares were vested was HK$1.14.

The total number of Shares available for issue under the 2023 Share Award Scheme is 106,072,600 Shares, representing approximately 8.16% of the total number of Shares in issue (1,299,276,000 Shares) as at the date of the 2024 Annual Report on 26 March 2025.

The above additional information does not affect other information contained in the 2024 Annual Report. Save as disclosed above, all other information in the 2024 Annual Report remains unchanged.

By order of the Board
Central China New Life Limited
Wang Jun
Chairman

Hong Kong, 19 August 2025

As at the date of this announcement, the Board comprises: (i) Mr. Wang Jun (Chairman) and Mr. Guo Liyuan as executive Directors; and (ii) Mr. Leong Chong, Ms. Luo Laura Ying and Ms. Xin Zhu as independent non-executive Directors.